Barry Kappel
Fondatore presso Sapience Therapeutics, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
David Scheinberg | M | 68 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 7 anni |
Cary Sucoff | M | 71 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 14 anni |
Howard H. Pien | M | 66 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 8 anni |
Robert Ruffolo | M | 74 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | - |
Christian Schade | M | 63 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | - |
Andrew Sanford | M | - |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 4 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Michael Messinger | M | 49 | 11 anni | |
Isaac Blech | M | 73 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | 9 anni |
Robert Nowinski | M | - | 5 anni | |
Julia Gregory | F | 71 | 4 anni | |
Roger Pomerantz | M | 67 | 9 anni | |
Sol Barer | M | 76 | 12 anni | |
Nancy Dong | F | 58 | 10 anni | |
Bogdanos Natalie | F | 55 | 9 anni | |
Sheng Da Zan | M | 61 | - | |
Michael Otto | M | 75 | 9 anni | |
David Low | M | 65 | 9 anni | |
Dimiter Tassev | M | - | - | |
Samuel Broder | M | 79 |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | - |
Daniel Couto | M | 52 | 5 anni | |
Richard Sykes | M | 79 | - | |
Michael Wittekind | M | 69 | 4 anni | |
David B. Huang | M | 49 | 3 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 23 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Barry Kappel
- Contatti personali